COSCIENS Biopharma Inc. Common Stock
CSCI
CSCI was delisted on the 3rd of September, 2025.
17 hedge funds and large institutions have $530K invested in COSCIENS Biopharma Inc. Common Stock in 2017 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 5 closing their positions.
500% more call options, than puts
Call options by funds: $12K | Put options by funds: $2K
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
6% more funds holding
Funds holding: 16 → 17 (+1)
0.01% more ownership
Funds ownership: 0.03% → 0.04% (+0.01%)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
59% less capital invested
Capital invested by funds: $1.3M → $530K (-$767K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$107K |
| 2 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$95.4K |
| 3 |
ARTA
A.R.T. Advisors
New York
|
+$82.7K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$77.3K |
| 5 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
+$62.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$153K |
| 2 |
Renaissance Technologies
New York
|
-$130K |
| 3 |
Millennium Management
New York
|
-$39K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$30.3K |
| 5 |
CG
Cutler Group
San Francisco,
California
|
-$14.1K |
CSCI Hedge Fund Activity: Q2 2017 in Review
17 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in COSCIENS Biopharma Inc. Common Stock (CSCI) for Q2 2017, worth a combined $530K — down 59% from $1.3M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new CSCI positions and 5 closed out — a net gain of 1 holder — while 3 added to existing stakes and 3 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $107K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $153K sold.
- 17 institutional investors held COSCIENS Biopharma Inc. Common Stock (CSCI) as of Q2 2017, up from 16 in Q1 2017.
- Funds reported $530K of COSCIENS Biopharma Inc. Common Stock stock for Q2 2017, down 59% quarter-over-quarter.
- 6 funds opened new COSCIENS Biopharma Inc. Common Stock positions in Q2 2017 and 5 closed out, a net change of +1 holder.
- The largest COSCIENS Biopharma Inc. Common Stock buyer in Q2 2017 was Sabby Management, an estimated $107K added.
- The largest COSCIENS Biopharma Inc. Common Stock seller in Q2 2017 was Susquehanna International Group, an estimated $153K sold.
Based on aggregated 13F filings for Q2 2017.